SMS Pharmaceuticals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹316 Cr +30.6% YoYSee revenue, profit and what management said. You are viewing Q3 FY25.
SP

SMS Pharmaceuticals Ltd

Q3 FY25Pharmaceuticals & Biotechnology

SMS Pharmaceuticals Q3 FY25: Revenue ₹173.35 Cr, PAT ₹18.24 Cr

Q3 FY25 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹173Cr
+7.5% YoY
−12.2% QoQ
Net profit
₹18Cr
+63.6% YoY
+28.6% QoQ
Margin
19%
+1 pp YoY
+3 pp QoQ

Based on SMS Pharmaceuticals Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹474
Market cap₹4.1K Cr
P/E40.5

The short version

Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). EBITDA for Q3FY25: ₹33.21 crore, up 15% YoY (Page 18 & 5) - EBITDA Margin for Q3FY25: 19%, up 120 bps YoY (Page 18 & 5) - Profit After Tax (PAT) for Q3FY25: ₹18.24 crore, up 59% YoY (Page 18 & 5) - PAT Margin for Q3FY25: 11%, up 341 bps YoY (Page 18) - Operating margin/outlook: The presentation notes margin expansion aided by backward integration and favorable product mix (Page 18).

From SMS Pharmaceuticals Ltd's Q3 FY25 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5).
  • Volume growth cited as a driver for revenue increase across the product portfolio (Page 18).
  • 9MFY25 revenue at ₹534.55 crore, up 15% YoY from ₹463.47 crore in 9MFY24 (Page 18).
  • EBITDA grew 15% YoY with margin expansion; PAT increased 59% YoY (Page 4, 5).
  • Outlook states "Robust growth is expected in revenue and profitability" driven by portfolio approach and cost optimization (Page 17).

2 more points from SMS Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what SMS Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Ongoing capex of ₹150 crore focused on backward integration and capacity expansion (Page 16).
  • Aim to achieve a production target of 1,000 MT per month for ibuprofen to achieve global scale (Page 16).
  • 2nd phase of backward integration project is complete; trial runs ongoing with commercial production set for March 2025 (Page 4).
  • Capacity expansion project remains on track for completion by FY26 (Page 4).

2 more points from SMS Pharmaceuticals Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what SMS Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

- Emphasis is on financial performance (revenue, EBITDA, PAT) and operational updates rather than order pipeline metrics.

SMS Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

SMS Pharmaceuticals Ltd Q3 FY25 results — key figures

SMS Pharmaceuticals Ltd Q3 FY25 reported results vs Q3 FY24, ₹ crore
₹ CrQ3 FY25Q3 FY24YoYQ2 FY25QoQ
Revenue173161+7.5%197-12.2%
Operating profit (EBITDA)3329+13.8%31+6.5%
Operating margin19%18%+1 pp16%+3 pp
Profit before tax2217+29.4%20+10%
Net profit (PAT)1811+63.6%14+28.6%
EPS (₹)2.151.36+58.1%1.66+29.5%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹316 Cr, net profit ₹40 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Wockhardt (Q3 FY25)

    725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…

  • NGL Fine Chem (Q3 FY25)

    Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key concall takeaways from NGL Fine Chem Ltd's Q3 FY25…

  • Shree Ganesh Rem (Q3 FY25)

    Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…

  • Themis Medicare (Q3 FY25)

    93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. Key concall takeaways from Themis Medicare Ltd's Q3 FY25 earnings call — and how it ranks against…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

SMS Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were SMS Pharmaceuticals Ltd Q3 FY25 results?

Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). EBITDA for Q3FY25: ₹33.21 crore, up 15% YoY (Page 18 & 5) - EBITDA Margin for Q3FY25: 19%, up 120 bps YoY (Page 18 & 5) - Profit After Tax (PAT) for Q3FY25: ₹18.24 crore, up 59% YoY (Page 18 & 5) - PAT Margin for Q3FY25: 11%, up 341 bps YoY (Page 18) - Operating margin/outlook: The presentation notes margin expansion aided by backward integration and favorable product mix (Page 18).

What is SMS Pharmaceuticals Ltd share price analysis?

SMS Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 40.5 with a market cap of ₹4,148 Cr. Investors should review the full earnings analysis for detailed insights.

Is SMS Pharmaceuticals Ltd planning capital expenditure?

Ongoing capex of ₹150 crore focused on backward integration and capacity expansion (Page 16).

Keep SMS Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.